Mark J. Biedka

Hospital Medicine
1211 Wilmington Avenue, UPMC Jameson Hospitalists
New Castle, PA 16105

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.

CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease.

Journal: Oncotarget
Published: September 15, 2017
Showing 1-1 of 1

Last Updated: 09/26/2026